Michigan Institute of Urology | Association Partnerships

Latest from Michigan Institute of Urology


Dr. Hafron on LUGPA 2021 and the rapidly evolving prostate and bladder cancer treatment landscapes

November 22, 2021

In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).

Dr. Hafron on PARP inhibitors in prostate cancer

November 16, 2021

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.